A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 321
- Population
- ALL · 18 Years
- Duration
- 2013-08-07 to 2017-03-02
- Intervention
- Ranibizumab; Verteporfin PDT; Sham PDT
- Comparator
- Ranibizumab monotherapy
- Outcomes measured
- Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12 - Study Eye — Baseline, Month 12; Number of Patients With Complete Polyp Regression From Baseline at Month 12 - Study Eye — Baseline, Month 12; Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) at Month 24 - Study Eye — Baseline, Month 24; Percentage of Patients With BCVA (Letters) Change From Baseline at Month 24 - Study Eye — Baseline, Month 24; Maintenance of BCVA (Within 5 Letter Change) at Month 12 and 24 Compared to BCVA at the Time Point of First Ranibizumab…; Change in BCVA at Month 12 and 24 Compared to the Time Point of First Ranibizumab Treatment Interruption — Month 3, Mon…; Percentage of Patients With Complete Polyp Regression at Months 6 and 24 - Study Eye — Month 6, Month 24; Percentage of Patients With Presence of Leakage at Month 6, Month 12 and Month 24 - Study Eye — Month 6, Month 12 and M…; Mean Change From Baseline in Investigator-Assessed Central Subfield Retinal Thickness (CSFT) at Month 24 - Study Eye —…; Total Number of Ranibizumab Injections Received in the Study Eye Prior to Month 12 — Baseline, Month 12; Total Number of Verteporfin/Sham PDT Injections Received in the Study Eye Prior to Month 12 — Baseline, Month 12; Total Number of Ranibizumab Injections Received in the Study Eye Prior to Month 24 — Baseline, Month 24; Total Number of Verteporfin/Sham PDT Injections Received in the Study Eye Prior to Month 24 — Baseline, Month 24; Total Number of Ranibizumab Injections Received in the Study Eye From Month 3 to Month 12 — Month 3, Month 12; Total Number of Ranibizumab Injections Received in the Study Eye From Month 3 to Month 24 — Month 3, Month 24; Mean Change From Baseline in Composite Scores, National Eye Institute Visual Functioning Questionnaire (NEI-VFQ-25) at…; Number of Ocular Adverse Events of the Study Eye Regardless of Study Drug Relationship up to Month 24, Any Primary Syst…; Number of Non-Ocular Adverse Events of the Study Eye Regardless of Study Drug Relationship up to Month 24, Any Primary…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 60% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 60%Source terminology contains a controlled topic term. Source terminology supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.